AMGN vs MRNA
By Alex · Tickerpine
Amgen Inc. vs Moderna, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | AMGN | MRNA |
|---|---|---|
| Price | $358.33 | $67.27 |
| Market cap | $193.39B | $26.69B |
| P/E ratio | 24.9 | — |
| ROE | 101.32% | -36.56% |
| Profit margin | 20.96% | -143.55% |
| Revenue growth | 5.80% | 260.20% |
| Dividend yield | 2.81% | — |
| Beta | 0.42 | 1.03 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
AMGN vs MRNA in plain English
- AMGN is the bigger company — about 7.2× the market cap of MRNA.
- AMGN earns a higher return on equity (101% vs -37%).
- MRNA is growing revenue faster (260% vs 6%).
- AMGN pays a dividend (2.81%) while the other effectively doesn't.
How would $1,000 have done in each?
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
MRNA return calculator
See what $1,000 in Moderna, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.